David Grandioso-Vas

David Grandioso-Vas

Auto-generated profile, based on publicly available information

David Grandioso-Vas

Department of Microbiology, La Paz University Hospital, Madrid, Spain. IdiPAZ Hospital La Paz Institute for Health Research, La Paz University Hospital , Madrid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CMCristina Marcelo
Cristina Marcelo
AGAlejandro De Gea Grela
Alejandro De Gea Grela
MPMaría Martínez Palazuelos
María Martínez Palazuelos
JVJavier Veganzones
Javier Veganzones
DGDavid Grandioso
David Grandioso
BDBeatriz Díaz-Pollán
Beatriz Díaz-Pollán
Ventriculitis is a complication of meningitis (community-acquired or nosocomial) or other central nervous system (CNS) infections such as brain abscess. They are associated with a different spectrum of microorganisms, from resistant gram-negative bacilli to staphylococci, that can lead serious illness with high mortality. Difficult-to-treat resistance (DTR) gram-negative bacilli may increase to 20% of deaths respective to susceptible isolates of the same bacteria. We present the first report of a clinical cured case of DTR Pseudomonas aeruginosa ventriculitis in which cefiderocol penetration into the CNS has been confirmed in blood and cerebrospinal fluid. Cefiderocol might be considered for difficult-to-treat CNS infections in view of the recent new cases published as well as our case.

17 July 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ECElvira Cobo-Vázquez
Elvira Cobo-Vázquez
DADavid Aguilera-Alonso
David Aguilera-Alonso
DGDavid Grandioso-Vas
David Grandioso-Vas
AGAnna Gamell
Anna Gamell
VRVictoria Rello-Saltor
Victoria Rello-Saltor
OGon behalf PedGAS-net Working Group
on behalf PedGAS-net Working Group
A global surge in pediatric invasive group A streptococcal infection (iGAS) was reported after autumn 2022. This study analyzed the epidemiology and severity of iGAS in Spain, comparing two periods; P1: pre-outbreak (January 2019-September 2022) versus P2: outbreak (October 2022-July 2023). Children ≤16 years with iGAS enrolled in the Spanish PedGAS-net (2019-2023), were included. Bacterial isolates were analyzed for emm typing, antibiotic susceptibility, and whole genome sequencing. Multivariate analysis identified risk factors for PICU admission and mortality. 558 cases were included; 307 (55.1%) were male, with a median age of 43.9 months (IQR:19.3-84.1). There were significantly more iGAS in P2 (35.7 vs. 4.5 cases/month, P < 0.001), with higher PICU admissions (51.3% vs. 30.8%, P < 0.001). Pneumonia was the most common syndrome (32.3%), with pleural effusion in 58.3%. Of the 130 samples available for emm-typing, the most frequent were emm1 (56.1%) and emm12 (27.1%). 245 (43.9%) required PICU admission. Factors associated with PICU were streptococcal toxic shock syndrome (STSS), pneumonia, necrotizing fasciitis, acute kidney failure, and previous consultation before diagnosis. The emm1 (especially M1UK) increased PICU risk. 11 children (2.0%) died. STSS, sepsis, and central nervous system infection were associated with mortality. In Spain, pediatric iGAS cases sharply increased during 2022-2023, with a remarkable increase in severity. Epidemiological surveillance of iGAS remains crucial.

18 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
ADAlejandro Díez-Vidal
Alejandro Díez-Vidal
FFFernando Fernández-Hinojal
Fernando Fernández-Hinojal
CMCristina Marcelo-Calvo
Cristina Marcelo-Calvo
BHBorja J. Hernández-García
Borja J. Hernández-García
ECEmilio Cendejas-Bueno
Emilio Cendejas-Bueno
BDBeatriz Díaz-Pollán
Beatriz Díaz-Pollán
Background: Ventriculitis is a severe central nervous system infection, often secondary to intraventricular device use or neurosurgical procedures, with high morbidity and mortality. Diagnostic criteria remain debated and treatment strategies lack standardization. Methods: We conducted a retrospective cohort study from 2014 to 2022 to describe the clinical characteristics, microbiological profile, treatment strategies, and outcomes of ventriculitis at a tertiary care center. Additionally, we compared outcomes before and after the implementation of an updated intraventricular device management protocol. Results: A total of 403 positive CSF cultures were identified during the study period. Among these, 87 fulfilled clinical and microbiological criteria for ventriculitis. Healthcare-associated cases predominated (73, 83.9%), with neurosurgical interventions (72, 82.8%) and external ventricular drain use (54, 62.1%) as the most prevalent risk factors. The most common pathogens were coagulase-negative Staphylococci (42, 48.3%), particularly Staphylococcus epidermidis (33, 37.9%). Fever (56, 64.4%) and altered consciousness (40, 45.9%) were the most frequent symptoms. Attributable mortality reached 33.3% (29/87), increasing to 39.1% (34/87) within one-year post-episode. The introduction of the updated protocol may have contributed to a reduction in mortality between the study periods [RR 0.45 (0.32–0.78) p=0.003]. Among discharged patients, 67.3% (37/55) experienced neurological sequelae. Predictors of higher mortality included CSF protein ≥1 mg/mL at diagnosis and a Glasgow Coma Scale score ≤8 during the clinical course. Conclusions: Ventriculitis remains a complex and life-threatening condition with considerable diagnostic and management challenges. Our findings suggest that standardized intraventricular device care protocols may contribute to improved outcomes, although further evaluation is needed.

27 June 2024 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
AMAlfredo Maldonado-Barrueco
Alfredo Maldonado-Barrueco
DGDavid Grandioso-Vas
David Grandioso-Vas
MRMario Ruiz-Bastián
Mario Ruiz-Bastián
JCJuana Cacho-Calvo
Juana Cacho-Calvo
CTCarlos Toro
Carlos Toro
IQInmaculada Quiles-Melero
Inmaculada Quiles-Melero

1 July 2024 in Revista Española de Quimioterapia
Verified
Journal Article
Open access
AMAlfredo Maldonado-Barrueco
Alfredo Maldonado-Barrueco
CSClaudia Sanz-González
Claudia Sanz-González
DGDavid Grandioso-Vas
David Grandioso-Vas
IFIker Falces-Romero
Iker Falces-Romero
JGJulio García-Rodriguez
Julio García-Rodriguez
IQInmaculada Quiles-Melero
Inmaculada Quiles-Melero